'Knock-down' of spinal CB1 receptors produces abnormal pain and elevates spinal dynorphin content in mice

Ahmet Dogrul, Luis R. Gardell, Shouwu Ma, Michael H. Ossipov, Frank Porreca, Josephine Lai

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Recent studies demonstrate the possible existence of tonic modulatory control of nociceptive input mediated by spinal cannabinoid receptors (CB1). Accordingly, it is predicted that a reduction in the spinal CB1 receptors may enhance sensitivity to sensory stimuli and a decrease in spinal antinociceptive potency to cannabinoid agonists. An antisense oligodeoxynucleotide (ODN) specific to the CB1 receptor was used to 'knock-down' CB1 receptors in the lumbar spinal cord and dorsal root ganglia by the local, repeated intrathecal (i.th.) administration of the ODN. This treatment resulted in a decrease in lumbar spinal CB1 receptor expression accompanied by a decrease in the response thresholds to both innocuous tactile and noxious thermal stimuli. The antinociceptive action of the CB1 agonist, WIN 55,212-2, by i.th. administration was also significantly attenuated after treatment with the antisense ODN. Similar treatment using a mismatch control ODN had no effect on receptor protein or on sensory thresholds. The effects of the antisense ODN treatment on sensory thresholds were fully reversed after discontinuation of the ODN injection. The antisense ODN treated rats also showed a significant increase in lumbar spinal dynorphin A. Acute i.th. injection of MK-801 or an antidynorphin antiserum blocked the antisense ODN-induced tactile and thermal hypersensitivity. These data support the possibility of endogenous inhibitory cannabinoid tone to limit spinal afferent input of thermal and tactile stimuli. Lifting of this inhibitory tone through a 'knock-down' of spinal CB1 receptors apparently lowers the thresholds for sensory input, as reflected by the actions of MK-801 to block tactile and thermal hypersensitivity. The increased spinal dynorphin may act to further promote afferent outflow and abnormal pain because sequestration of spinal dynorphin with antiserum also reverses the manifestations of abnormal pain following knock-down of CB1 receptors.

Original languageEnglish (US)
Pages (from-to)203-209
Number of pages7
JournalPain
Volume100
Issue number1-2
DOIs
StatePublished - Nov 2002

Fingerprint

Dynorphins
Cannabinoid Receptor CB1
Oligodeoxyribonucleotides
Pain
Touch
Sensory Thresholds
Hot Temperature
Dizocilpine Maleate
Immune Sera
Spinal Cord
Hypersensitivity
Cannabinoid Receptor Agonists
Injections
Cannabinoids
Spinal Nerve Roots
Spinal Ganglia
Therapeutics

Keywords

  • Abnormal pain
  • Antisense
  • Knock-down
  • Spinal cannabinoid receptors
  • Spinal dynorphin

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Neuroscience(all)
  • Pharmacology
  • Clinical Psychology

Cite this

'Knock-down' of spinal CB1 receptors produces abnormal pain and elevates spinal dynorphin content in mice. / Dogrul, Ahmet; Gardell, Luis R.; Ma, Shouwu; Ossipov, Michael H.; Porreca, Frank; Lai, Josephine.

In: Pain, Vol. 100, No. 1-2, 11.2002, p. 203-209.

Research output: Contribution to journalArticle

Dogrul, Ahmet ; Gardell, Luis R. ; Ma, Shouwu ; Ossipov, Michael H. ; Porreca, Frank ; Lai, Josephine. / 'Knock-down' of spinal CB1 receptors produces abnormal pain and elevates spinal dynorphin content in mice. In: Pain. 2002 ; Vol. 100, No. 1-2. pp. 203-209.
@article{924253cc87364f97b92be02c3d43fc65,
title = "'Knock-down' of spinal CB1 receptors produces abnormal pain and elevates spinal dynorphin content in mice",
abstract = "Recent studies demonstrate the possible existence of tonic modulatory control of nociceptive input mediated by spinal cannabinoid receptors (CB1). Accordingly, it is predicted that a reduction in the spinal CB1 receptors may enhance sensitivity to sensory stimuli and a decrease in spinal antinociceptive potency to cannabinoid agonists. An antisense oligodeoxynucleotide (ODN) specific to the CB1 receptor was used to 'knock-down' CB1 receptors in the lumbar spinal cord and dorsal root ganglia by the local, repeated intrathecal (i.th.) administration of the ODN. This treatment resulted in a decrease in lumbar spinal CB1 receptor expression accompanied by a decrease in the response thresholds to both innocuous tactile and noxious thermal stimuli. The antinociceptive action of the CB1 agonist, WIN 55,212-2, by i.th. administration was also significantly attenuated after treatment with the antisense ODN. Similar treatment using a mismatch control ODN had no effect on receptor protein or on sensory thresholds. The effects of the antisense ODN treatment on sensory thresholds were fully reversed after discontinuation of the ODN injection. The antisense ODN treated rats also showed a significant increase in lumbar spinal dynorphin A. Acute i.th. injection of MK-801 or an antidynorphin antiserum blocked the antisense ODN-induced tactile and thermal hypersensitivity. These data support the possibility of endogenous inhibitory cannabinoid tone to limit spinal afferent input of thermal and tactile stimuli. Lifting of this inhibitory tone through a 'knock-down' of spinal CB1 receptors apparently lowers the thresholds for sensory input, as reflected by the actions of MK-801 to block tactile and thermal hypersensitivity. The increased spinal dynorphin may act to further promote afferent outflow and abnormal pain because sequestration of spinal dynorphin with antiserum also reverses the manifestations of abnormal pain following knock-down of CB1 receptors.",
keywords = "Abnormal pain, Antisense, Knock-down, Spinal cannabinoid receptors, Spinal dynorphin",
author = "Ahmet Dogrul and Gardell, {Luis R.} and Shouwu Ma and Ossipov, {Michael H.} and Frank Porreca and Josephine Lai",
year = "2002",
month = "11",
doi = "10.1016/S0304-3959(02)00302-0",
language = "English (US)",
volume = "100",
pages = "203--209",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - 'Knock-down' of spinal CB1 receptors produces abnormal pain and elevates spinal dynorphin content in mice

AU - Dogrul, Ahmet

AU - Gardell, Luis R.

AU - Ma, Shouwu

AU - Ossipov, Michael H.

AU - Porreca, Frank

AU - Lai, Josephine

PY - 2002/11

Y1 - 2002/11

N2 - Recent studies demonstrate the possible existence of tonic modulatory control of nociceptive input mediated by spinal cannabinoid receptors (CB1). Accordingly, it is predicted that a reduction in the spinal CB1 receptors may enhance sensitivity to sensory stimuli and a decrease in spinal antinociceptive potency to cannabinoid agonists. An antisense oligodeoxynucleotide (ODN) specific to the CB1 receptor was used to 'knock-down' CB1 receptors in the lumbar spinal cord and dorsal root ganglia by the local, repeated intrathecal (i.th.) administration of the ODN. This treatment resulted in a decrease in lumbar spinal CB1 receptor expression accompanied by a decrease in the response thresholds to both innocuous tactile and noxious thermal stimuli. The antinociceptive action of the CB1 agonist, WIN 55,212-2, by i.th. administration was also significantly attenuated after treatment with the antisense ODN. Similar treatment using a mismatch control ODN had no effect on receptor protein or on sensory thresholds. The effects of the antisense ODN treatment on sensory thresholds were fully reversed after discontinuation of the ODN injection. The antisense ODN treated rats also showed a significant increase in lumbar spinal dynorphin A. Acute i.th. injection of MK-801 or an antidynorphin antiserum blocked the antisense ODN-induced tactile and thermal hypersensitivity. These data support the possibility of endogenous inhibitory cannabinoid tone to limit spinal afferent input of thermal and tactile stimuli. Lifting of this inhibitory tone through a 'knock-down' of spinal CB1 receptors apparently lowers the thresholds for sensory input, as reflected by the actions of MK-801 to block tactile and thermal hypersensitivity. The increased spinal dynorphin may act to further promote afferent outflow and abnormal pain because sequestration of spinal dynorphin with antiserum also reverses the manifestations of abnormal pain following knock-down of CB1 receptors.

AB - Recent studies demonstrate the possible existence of tonic modulatory control of nociceptive input mediated by spinal cannabinoid receptors (CB1). Accordingly, it is predicted that a reduction in the spinal CB1 receptors may enhance sensitivity to sensory stimuli and a decrease in spinal antinociceptive potency to cannabinoid agonists. An antisense oligodeoxynucleotide (ODN) specific to the CB1 receptor was used to 'knock-down' CB1 receptors in the lumbar spinal cord and dorsal root ganglia by the local, repeated intrathecal (i.th.) administration of the ODN. This treatment resulted in a decrease in lumbar spinal CB1 receptor expression accompanied by a decrease in the response thresholds to both innocuous tactile and noxious thermal stimuli. The antinociceptive action of the CB1 agonist, WIN 55,212-2, by i.th. administration was also significantly attenuated after treatment with the antisense ODN. Similar treatment using a mismatch control ODN had no effect on receptor protein or on sensory thresholds. The effects of the antisense ODN treatment on sensory thresholds were fully reversed after discontinuation of the ODN injection. The antisense ODN treated rats also showed a significant increase in lumbar spinal dynorphin A. Acute i.th. injection of MK-801 or an antidynorphin antiserum blocked the antisense ODN-induced tactile and thermal hypersensitivity. These data support the possibility of endogenous inhibitory cannabinoid tone to limit spinal afferent input of thermal and tactile stimuli. Lifting of this inhibitory tone through a 'knock-down' of spinal CB1 receptors apparently lowers the thresholds for sensory input, as reflected by the actions of MK-801 to block tactile and thermal hypersensitivity. The increased spinal dynorphin may act to further promote afferent outflow and abnormal pain because sequestration of spinal dynorphin with antiserum also reverses the manifestations of abnormal pain following knock-down of CB1 receptors.

KW - Abnormal pain

KW - Antisense

KW - Knock-down

KW - Spinal cannabinoid receptors

KW - Spinal dynorphin

UR - http://www.scopus.com/inward/record.url?scp=0036844373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036844373&partnerID=8YFLogxK

U2 - 10.1016/S0304-3959(02)00302-0

DO - 10.1016/S0304-3959(02)00302-0

M3 - Article

VL - 100

SP - 203

EP - 209

JO - Pain

JF - Pain

SN - 0304-3959

IS - 1-2

ER -